par de Valeriola, Dominique 
;Awada, Ahmad ;Roy, J A;Di Leo, Angelo ;Biganzoli, Laura ;Piccart-Gebhart, Martine
Référence Drugs, 54, 3, page (385-413)
Publication Publié, 1997-09
;Awada, Ahmad ;Roy, J A;Di Leo, Angelo ;Biganzoli, Laura ;Piccart-Gebhart, Martine Référence Drugs, 54, 3, page (385-413)
Publication Publié, 1997-09
Article révisé par les pairs
| Résumé : | Although the management of breast cancer has improved over the past few decades, it remains an important challenge for the clinician. Cytotoxic chemotherapy and hormonotherapy, when given in the adjuvant setting, have a definitive though modest impact on the outcome of early-stage breast cancer. In metastatic disease, these therapies help to provide substantial palliation of symptoms but have a limited impact on survival. The discovery of vinorelbine and the taxanes, paclitaxel and docetaxel, certainly represented the most encouraging clinical development of the 1980s in breast cancer therapy. Several other new cytotoxic agents have been recognised for their potential in the treatment of this disorder. Many of them are only in a very early phase of their clinical development and it remains to be proven that they will have a major role in daily practice in the near future. |
